]>

IRCT20150630022991N10 IRCT 2018-03-21 Babol University of Medical Sciences Efficacy of Escitalopram, Venlafaxine and Buspirone in Irritable Bowel Syndrome Comparison of the Efficacy of Escitalopram, Venlafaxine and Buspirone on the Symptoms and Quality of Life in Irritable Bowel Syndrome Patients 2017-12-22 anticipated 90 Complete https://irct.ir/trial/30111 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The individuals are randomly assigned to one of the three study groups with the help of a random number table and receive the intervention of the same group, Blinding description: In each of the three study groups, the drug is delivered to the patient in the form of a capsule, and the patient does not know what type of drug is used. 2-3 Irritable bowel syndrome. Intervention 1: Intervention group 1: Daily 10-20 milligram Escitalopram manufactured in Sobhan Pharmaceutical Company for 8 weeks. Intervention 2: Intervention group 2: Daily 75-375 milligram Venlafaxine manufactured in Abidi Pharmaceutical Company for 8 weeks. Intervention 3: Control group: Daily 15-60 milligram Buspirone manufactured in Sobhan Pharmaceutical Company for 8 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information.

public Sussan Moudi, MD

Department of Psychiatry, Shahid Yahyanejad Hospital, Babol

Babol Iran (Islamic Republic of) 4718747415 +98 11323268823 sussan.mouodi@gmail.com Babol University of Medical Sciences scientific Sussan Moudi, MD

Department of Psychiatry, Shahid Yahyanejad Hospital, Babol

Babol Iran (Islamic Republic of) 4718747415 +98 11 3219 0624 sussan.mouodi@gmail.com Babol University of Medical Sciences Iran (Islamic Republic of) The Presence of ROME-III Diagnostic Criteria for Diagnosis of Irritable Bowel Syndrome To Provide the Informed Consent Form of the Patient for Participation in the Study 18 years no limit Both Age under 18 years Allergy to Escitalopram, Venlafaxine or Buspirone The presence of warning signs such as chronic fever, weight loss, gastrointestinal bleeding Pregnancy and breast feeding Use of any drug that can affect the bowel function (such as laxatives, anti-diarrhea, antibiotics and probiotics) within one month before entering the study Known cases of lactose intolerance Severe physical illnesses, mental retardation, dementia, psychosis, and the existence of serious suicidal ideation and substance dependence that affects patients' compliance with the study protocol K58 Irritable bowel syndrome Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group 1: Daily 10-20 milligram Escitalopram manufactured in Sobhan Pharmaceutical Company for 8 weeks Intervention group 2: Daily 75-375 milligram Venlafaxine manufactured in Abidi Pharmaceutical Company for 8 weeks Control group: Daily 15-60 milligram Buspirone manufactured in Sobhan Pharmaceutical Company for 8 weeks Irritable bowel syndrome symptoms. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to ROME-III diagnostic criteria. Patient´s quality of life. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to the quality of life questionnaire IBS_QOL. The drug side effects. Timepoint: At the fourth and eighth weeks of the intervention. Method of measurement: Visit of the patient. Babol University of Medical Sciences Approved 2017-10-15 Ethics Committee of Babol University of Medical Sciences Ganjafrooz Avenue, Babol Babol Mazandaran Iran (Islamic Republic of)